PharmaShots Weekly Snapshot (October 15 – 20, 2018)

  1. Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US

 

Published: 18 Oct, 2018 | Tags: Mylan, Launches, MPA Injectable Suspension, Prevention of  Pregnancy, the US

 

  1. Janssen Pharmaceuticals (J&J) Receives Health Canada’s Approval for Invokana (canagliflozin) in MACE Reduction

 

Published: 17 Oct, 2018 | Tags: Janssen Pharmaceuticals, (J&J), Receives, Health Canada’s, Approval, Invokana (canagliflozin), MACE Reduction

 

  1. Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda MonoTx) Study in Hepatitis Delta Virus (HDV) Infection

 

Published: 18 Oct, 2018 | Tags: Eiger Pharmaceuticals, Reports, Results, Lambda, P-II, LIMT (Lambda Monotherapy) Study, Hepatitis Delta Virus (HDV) Infection, LIFT, LIMT

 

  1. Allergan Announces Completion of UBR-MD-04 & 3110-105-002 Study for Treatment of Migrane

 

Published: 17 Oct, 2018 | Tags: Allergan, Announces, Completion, UBR-MD-04 & 3110-105-002 Study, Treatment, Migrane, Ubrogepant

 

  1. Axsome Therapeutics Receives FDA’s Orphan Drug Designation for AXS-12 (reboxetine) to Treat Narcolepsy

Published: 17 Oct, 2018 |Tags: Axsome Therapeutics, Receives, FDA, Orphan Drug Designation, AXS-12 (reboxetine), Treat,  Narcolepsy

 

  1. Novartis to Acquire Endocyte for Expansion of its Investigational Radioligand Therapy (RLT) Platform

 

Published: 18 Oct, 2018 |Tags: Novartis, Acquire, Endocyte, Expansion , Investigational Radioligand Therapy (RLT) Platform, Lu-PSMA-617, Ac-PSMA-617

 

  1. AbbVie Announces FDA’s Acceptance of sNDA for PR for Imbruvica (ibrutinib) + Gazyva (Obinutuzumab)

 

Published: 17 Oct, 2018 |Tags: AbbVie, FDA, Acceptance, sNDA, PR, Imbruvica (ibrutinib), (Obinutuzumab) Gazyva

 

  1. Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health

 

Published: 15 Oct, 2018 |Tags: Palette Life Sciences, Signs, Worldwide, Commercialization, Development, Agreement , Nestle Skin Health, Deflux IV  ,Solesta, Barrigel

 

 

  1. Samsung Biogen Launches Imraldi (adalimumab, biosimilar) in EU for 14 Autoimmune Conditions

 

Published:17 Oct, 2018 |Tags: Samsung Biogen, Launches, Imraldi (adalimumab, biosimilar), EU, 14 Autoimmune Conditions, Benepalitm , Flixabitm

 

  1. Voyager to Present Preclinical Data of VY-HTT01 & VY-SOD102 at ESGCT 2018

 

Published: 17 Oct, 2018 |Tags: Voyager, Present, Preclinical Data, VY-HTT01, VY-SOD102, ESGCT    2018

 

  1. Ferring Signs a Research Colllaboration with Evotec to Develop Novel Small Molecule Therapies

 

Published:17 Oct, 2018 |Tags: Ferring, Signs , Research Colllaboration,  Evotec , Develop, Novel Small Molecule Therapies

 

  1. Regeneron’s Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

 

Published:16 Oct, 2018 |Tags: Regeneron,  Dupixent (Dupilumab) ,Achieves, 1EP & 2EP,two P-III, Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

 

  1. AstraZeneca’s Lynparza (olaparib) Receives Fourth FDA’s Orphan Drug Designation to Treat Pancreatic Cancer

 

Published:16 Oct, 2018 |Tags: AstraZeneca,  Lynparza (olaparib), Receives , Fourth, FDA, Orphan Drug Designation, Treat, Pancreatic Cancer

 

  1. Google Developed AI System for Easy Detection of Last Stage Breast Cancer with 99% Accuracy

 

Published:12 Oct, 2018 |Tags: Google, Developed, AI System, Easy Detection, Last Stage Breast Cancer, 99% Accuracy, LYNA, Inception-v3

 

  1. Novartis Reports Results of Five-year P-III MEASURE 1 and FUTURE 1 study for AS and PsA

 

Published:16 Oct, 2018 |Tags: Novartis, Reports, Results ,Five-year, P-III ,MEASURE 1 and FUTURE 1 study , AS and PsA

 

  1. Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

 

Published: 16 Oct, 2018 |Tags: Amgen, Launches, Amgevita (adalimumab, biosimilar),  Post, EU Approval , Treat, Inflammatory Diseases

 

  1. Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA

 

Published: 15 Oct, 2018 |Tags: Sarepta, Signs, Exclusive, Global (Except EU) , License Agreement, Lysogene, LYS-SAF302, Treat, MPS IIIA

 

  1. Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study

 

Published: 15 Oct, 2018 |Tags: Roche, Reports, Kadcyla (trastuzumab emtansine) ,Herceptin (trastuzumab), Achieve ,1EP, P-III KATHERINE study

 

  1. Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies

 

Published: 11 Oct, 2018 |Tags: Themis Biosciences ,Signs,Exclusive, License Agreement,Max-Planck-Innovation for Oncolytic Virotherapies

 

  1. Therapiva Private Acquires Dr. Reddy’s API manufacturing Unit Jeedimetla, Hyderabad

 

Published: 15 Oct, 2018 |Tags: Therapiva Private, Acquires, Dr. Reddy’s ,API manufacturing Unit ,Jeedimetla, Hyderabad, M&A

 

  1. Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine)

 

Published:12 Oct, 2018 |Tags: Merck, Terminates , Development ,Commercialization, Deal, Samsung Bioepis, Lusduna Nexvue (insulin glargine)

 

  1. Roche Announces Global Launch of NGS AVENIO Tumor Tissue Analysis Kits

 

Published: 15 Oct, 2018 |Tags: Roche, Reports, Kadcyla (trastuzumab emtansine) ,Herceptin

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post